文献速递乳腺MR

基于MRI的深度学习影像组学无创识别HER2低表达状态并预测乳腺癌患者无病生存期

Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer.
PubMed 文献 · Eur Radiol · 2023-08-19

本研究回顾性纳入两家机构共481例术前行MRI的乳腺癌患者,构建基于传统影像组学特征与深度语义分割特征影像组学的深度学习影像组学(DLR)模型评估HER2状态,并分析HER2低表达患者的无病生存期(DFS)。DLR模型在训练集和验证集中区分HER2阴性 vs HER2过表达的AUC分别为0.868和0.763,区分HER2低表达 vs HER2零表达的AUC分别为0.855和0.750;Cox回归显示DLR模型预测评分(HR 0.175,p=0.024)与病灶大小(HR 1.043,p=0.009)为DFS的独立预测因素。

要点

  • DLR模型可无创区分HER2低表达与HER2零表达,验证集AUC 0.750。
  • DLR模型预测评分(HR 0.175,p=0.024)与病灶大小(HR 1.043,p=0.009)为DFS独立预测因素。
  • DLR模型区分HER2表达的效能优于传统影像组学模型或DSFR模型。

核心结论

  • 基于MRI的DLR模型可无创评估HER2状态,并展现预测HER2低表达患者DFS的前景。

研究设计与样本

  • 回顾性研究,纳入两家机构共481例术前行MRI的乳腺癌患者,提取传统影像组学特征与深度语义分割特征影像组学(DSFR)特征分别建模,再取两模型输出概率平均值构建DLR模型评估HER2状态,并以Kaplan-Meier分析和多因素Cox比例风险模型分析DFS。

诊断标准与关键数值

  • DLR模型区分HER2阴性 vs HER2过表达:训练集AUC 0.868,验证集AUC 0.763。

临床应用与阅片要点

  • DLR模型预测评分与病灶大小为DFS的独立预测因素,可用于HER2低表达状态的无创识别并辅助预后评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: This study aimed to establish a MRI-based deep learning radiomics (DLR) signature to predict the human epidermal growth factor receptor 2 (HER2)-low-positive status and further verified the difference in prognosis by the DLR model.

METHODS: A total of 481 patients with breast cancer who underwent preoperative MRI were retrospectively recruited from two institutions. Traditional radiomics features and deep semantic segmentation feature-based radiomics (DSFR) features were extracted from segmented tumors to construct models separately. Then, the DLR model was constructed to assess the HER2 status by averaging the output probabilities of the two models. Finally, a Kaplan‒Meier survival analysis was conducted to explore the disease-free survival (DFS) in patients with HER2-low-positive status. The multivariate Cox proportional hazard model was constructed to further determine the factors associated with DFS.

RESULTS: First, the DLR model distinguished between HER2-negative and HER2-overexpressing patients with AUCs of 0.868 and 0.763 in the training and validation cohorts, respectively. Furthermore, the DLR model distinguished between HER2-low-positive and HER2-zero patients with AUCs of 0.855 and 0.750, respectively. Cox regression analysis showed that the prediction score obtained using the DLR model (HR, 0.175; p = 0.024) and lesion size (HR, 1.043; p = 0.009) were significant, independent predictors of DFS.

CONCLUSIONS: We successfully constructed a DLR model based on MRI to noninvasively evaluate the HER2 status and further revealed prospects for predicting the DFS of patients with HER2-low-positive status.

CLINICAL RELEVANCE STATEMENT: The MRI-based DLR model could noninvasively identify HER2-low-positive status, which is considered a novel prognostic predictor and therapeutic target.

KEY POINTS: • The DLR model effectively distinguished the HER2 status of breast cancer patients, especially the HER2-low-positive status. • The DLR model was better than the traditional radiomics model or DSFR model in distinguishing HER2 expression. • The prediction score obtained using the model and lesion size were significant independent predictors of DFS.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Guo Y, Xie X, Tang W, et al. Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer. Eur Radiol. 2023. PMID: 37597033. doi:10.1007/s00330-023-09990-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。